This press release is a scientific data update, not a regulatory or financial catalyst. The 40% HBsAg reduction signal in a small Phase 1 subgroup is encouraging but early — watch for Phase 2 initiation and enrollment updates for pevifoscorvir sodium.
Price Chart
Executive Summary
Aligos Therapeutics presented 10 posters at the EASL Congress 2026, including new Phase 1 long-term follow-up data for pevifoscorvir sodium in chronic HBV infection. The data suggest 40% of HBeAg+ patients with HBsAg ≥3,000 IU/mL achieved reductions qualifying them for potential functional cure regimens, and preclinical data showed additive-to-synergistic effects when combined with the ASO ALG-170675.
Key Facts
- Phase 1 long-term follow-up data on 10 HBeAg+ subjects: 4 of 9 (44%) maintained HBV DNA below LLOQ during ≥24 weeks of NA-only follow-up post 96-week pevifoscorvir monotherapy.
- 40% of evaluable HBeAg+ participants with baseline HBsAg ≥3,000 IU/mL achieved HBsAg <3,000 IU/mL at week 48, suggesting potential eligibility for functional cure therapy with an ASO agent.
- Preclinical in vitro data showed additive-to-synergistic antiviral effects when ALG-001075 (active parent of pevifoscorvir) was combined with the ASO ALG-170675.
- Pevifoscorvir sodium is being developed as a potential first-in-class CAM-E with a proposed secondary mechanism reducing the cccDNA reservoir.
- Data presented at EASL Congress 2026, May 27-30, in Barcelona, Spain. No new financial data, regulatory filing, or enrollment milestones were announced.
Financial Impact
No revenue, financial results, or guidance were disclosed. Impact on valuation depends on subsequent clinical and regulatory milestones.
Risk Factors
- Phase 1 data are from 10 subjects — very small sample size limits statistical reliability.
- No regulatory or Phase 2 enrollment catalysts in this update; 40% HBsAg reduction threshold is a biomarker, not a functional cure endpoint.
- Pevifoscorvir sodium is still early-stage; competition from other CAM-E and ASO programs in HBV could limit differentiation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $5.51 $6.77 | ▲ +22.87% | ▲ +21.65% | $4.63 (−15.97%) |
Jun 26, 2026 17w ago | 8-K | $5.43 $5.85 | ▲ +7.73% | ▲ +6.35% | $4.63 (−14.73%) |
May 27, 2026 21w ago | Press Release | $5.60 $5.14 | ▼ −8.21% | ▼ −8.68% | $4.63 (−17.32%) |
Apr 16, 2026 27w ago | Press Release | $7.66 $6.13 | ▼ −19.97% | ▼ −20.96% | $4.63 (−39.56%) |
Apr 14, 2026 27w ago | Press Release | $7.42 $6.51 | ▼ −12.26% | ▼ −13.90% | $4.63 (−37.60%) |
Mar 5, 2026 33w ago | 8-K | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.63 (−30.48%) |
Mar 5, 2026 33w ago | Press Release | $6.66 $7.41 | ▲ +11.26% | ▲ +13.50% | $4.63 (−30.48%) |
Feb 28, 2026 34w ago | Institutional Cluster | $6.97 $7.03 | ▲ +0.86% | ▲ +2.07% | $4.63 (−33.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers